ArticleThe Journal of urology2012

Re: Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

No numbers read from the abstract.

Not cited yet